Display options
Cite
Jan TA, Remenschneider AK, Halpin C, et al. Third-generation bisphosphonates for cochlear otosclerosis stabilizes sensorineural hearing loss in long-term follow-up. Laryngoscope Investig Otolaryngol. 2017;2(5):262-268doi: 10.1002/lio2.91.
Jan, T. A., Remenschneider, A. K., Halpin, C., Seton, M., McKenna, M. J., & Quesnel, A. M. (2017). Third-generation bisphosphonates for cochlear otosclerosis stabilizes sensorineural hearing loss in long-term follow-up. Laryngoscope investigative otolaryngology, 2(5), 262-268. https://doi.org/10.1002/lio2.91
Jan, Taha A, et al. "Third-generation bisphosphonates for cochlear otosclerosis stabilizes sensorineural hearing loss in long-term follow-up." Laryngoscope investigative otolaryngology vol. 2,5 (2017): 262-268. doi: https://doi.org/10.1002/lio2.91
Jan TA, Remenschneider AK, Halpin C, Seton M, McKenna MJ, Quesnel AM. Third-generation bisphosphonates for cochlear otosclerosis stabilizes sensorineural hearing loss in long-term follow-up. Laryngoscope Investig Otolaryngol. 2017 Sep 21;2(5):262-268. doi: 10.1002/lio2.91. eCollection 2017 Oct. PMID: 29094069; PMCID: PMC5655565.
Copy Download .nbib Format: NLM
Share it on

Laryngoscope Investig Otolaryngol. 2017 Sep 21;2(5):262-268. doi: 10.1002/lio2.91. eCollection 2017 Oct.

Third-generation bisphosphonates for cochlear otosclerosis stabilizes sensorineural hearing loss in long-term follow-up.

Laryngoscope investigative otolaryngology

Taha A Jan, Aaron K Remenschneider, Christopher Halpin, Margaret Seton, Michael J McKenna, Alicia M Quesnel

Affiliations

  1. Department of Otolaryngology , Massachusetts Eye and Ear Harvard Medical School Boston Massachusetts U.S.A.
  2. Department of Medicine , Brigham and Women's Hospital Harvard Medical School Boston Massachusetts U.S.A.

PMID: 29094069 PMCID: PMC5655565 DOI: 10.1002/lio2.91

Abstract

OBJECTIVE: To assess long-term hearing outcomes in patients treated with third-generation bisphosphonates for otosclerosis-related progressive sensorineural hearing loss (SNHL).

STUDY DESIGN: Retrospective case series review.

METHODS: We performed a retrospective case series review of patients with otosclerosis and progressive SNHL. Patients were treated with either risedronate or zoledronate after a diagnosis of otosclerosis with a significant SNHL component. Bone conduction pure tone threshold averages (BC-PTAs) and word recognition scores (WRS) before and after bisphosphonate administration in long-term follow-up was analyzed. Significant change in BC-PTA was defined as greater than 10dB or between 4% and 18% in WRS based on binomial variance.

RESULTS: Seven patients were identified and 14 ears met inclusion criteria. Three patients were female and the mean age was 48.3 ± 10.3 years. The mean duration between treatment with bisphosphonate administration and long-term post-treatment follow-up audiometry was 87.6 ± 18.3 months, with a range of 61.6 to 109.1 months and median of 89.2 months. Analysis using BC-PTA and WRS demonstrated that 11 ears remained stable while 2 improved and 1 worsened. No patient experienced any major complication as the result of bisphosphonate therapy.

CONCLUSION: Treatment with third-generation bisphosphonates is associated with stability in otosclerosis-related sensorineural hearing over 5- to 9-year period. These results suggest that such medications may prevent the progression of SNHL in patients with otosclerosis.

LEVEL OF EVIDENCE: 4 (Case series).

Keywords: Otosclerosis; bisphosphonates; cochlear otosclerosis; sensorineural hearing loss

References

  1. Otol Neurotol. 2013 Jun;34(4):778-9 - PubMed
  2. Am J Otolaryngol. 1989 Jan-Feb;10(1):1-12 - PubMed
  3. Hear Res. 2009 Sep;255(1-2):22-32 - PubMed
  4. Acta Otolaryngol Suppl. 1969;253:1-68 - PubMed
  5. Otol Neurotol. 2016 Feb;37(2):e7-8 - PubMed
  6. Otol Neurotol. 2005 Sep;26(5):983-7 - PubMed
  7. Otol Neurotol. 2016 Mar;37(3):218-22 - PubMed
  8. BMJ. 2015 Sep 02;351:h3783 - PubMed
  9. Otol Neurotol. 2016 Dec;37(10 ):1489-1496 - PubMed
  10. Otol Neurotol. 2005 Jul;26(4):602-9 - PubMed
  11. Otolaryngol Head Neck Surg. 1993 Sep;109(3 Pt 1):461-7 - PubMed
  12. Laryngol Rhinol Otol (Stuttg). 1987 Apr;66(4):167-71 - PubMed
  13. Osteoporos Int. 2008 Jun;19(6):733-59 - PubMed
  14. Neuroscience. 2008 Nov 19;157(2):405-13 - PubMed
  15. Adv Otorhinolaryngol. 2007;65:25-30 - PubMed
  16. Int Tinnitus J. 2008;14(2):92-6 - PubMed
  17. J Speech Hear Res. 1978 Sep;21(3):507-18 - PubMed
  18. Otol Neurotol. 2015 Jul;36(6):953-60 - PubMed
  19. Hear Res. 2015 Dec;330(Pt A):51-6 - PubMed
  20. Ann Otol Rhinol Laryngol. 2010 Apr;119(4):215-24 - PubMed
  21. J Speech Hear Disord. 1952 Sep;17(3):321-37 - PubMed
  22. Otolaryngol Head Neck Surg. 2012 Nov;147(5):803-7 - PubMed
  23. J Laryngol Otol. 2010 Jun;124(6):583-6 - PubMed
  24. Am J Otolaryngol. 2000 Mar-Apr;21(2):116-8 - PubMed
  25. Radiology. 1985 Sep;156(3):703-8 - PubMed
  26. Otol Neurotol. 2001 Sep;22(5):596-602 - PubMed
  27. Otol Neurotol. 2012 Oct;33(8):1308-14 - PubMed
  28. Neurobiol Dis. 2013 Aug;56:25-33 - PubMed
  29. Bone. 2012 Jun;50(6):1389-93 - PubMed

Publication Types

Grant support